Cassava Sciences Inc (SAVA)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Remi Barbier
Employees:
20
7801 N CAPITAL OF TEXAS HIGHWAY, SUITE 260, AUSTIN, TX 78731
512-501-2444

Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial.

Data derived from most recent annual or quarterly report
Market Cap 601.322 Million Shares Outstanding17.22 Million Avg 30-day Volume 1.461 Million
P/E Ratio0.0 Dividend Yield0.0 EPS-0.24
Price to Revenue0.0 Debt to Equity0.0 EBITDA-71.296 Million
Price to Book Value8.4324 Operating Margin0.0 Enterprise Value1.501 Billion
Current Ratio22.06 EPS Growth-2.315 Quick Ratio21.023
1 Yr BETA 1.0568 52-week High/Low 62.49 / 13.84 Profit Margin0.0
Operating Cash Flow Growth-174.4654 Altman Z-Score115.4308 Free Cash Flow to Firm -49.485 Million
View SEC Filings from SAVA instead.

View recent insider trading info

Funds Holding SAVA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding SAVA

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-22:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-07:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-10-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-09-23:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-05-09:
    Item 5.07: Submission of Matters to a Vote of Security Holders
  • 8-K: filed on 2022-05-05:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-04-26:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-01-06:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    9.4 Thousand total shares from 1 transactions

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    COOK ROBERT CHRISTOPHER SVP & GENERAL COUNSEL

    • Officer
    0 2022-10-28 2

    FRIEDMANN NADAV CHIEF MEDICAL OFFICER

    • Officer
    • Director
    120,677 2022-10-03 3

    ROBERTSON SANFORD

    • Director
    1,027,567 2022-09-08 3

    BARRY RICHARD

    • Director
    186,159 2022-08-23 1

    KUPIEC JAMES WILLIAM CHIEF CLINICAL DEV. OFFICER

    • Officer
    2,500 2022-08-23 1

    SCHOEN ERIC CHIEF FINANCIAL OFFICER

    • Officer
    21,800 2022-08-12 2

    BARBIER REMI PRESIDENT AND CEO

    • Officer
    • Director
    1,143,829 2022-06-06 2

    GUSSIN ROBERT Z

    • Director
    8,410 2022-03-29 1

    O DONNELL MICHAEL J

    • Director
    4,870 2021-03-16 0

    SCANNON PATRICK J MD PHD

    • Director
    0 2020-12-11 0

    RAMASASTRY SAIRA

    • Director
    0 2019-12-13 0

    ARMISTICE CAPITAL, LLC

    ARMISTICE CAPITAL MASTER FUND LTD.

    BOYD STEVEN

    • 10% Owner
    No longer subject to file 2018-10-03 0

    RODDY PETER S CHIEF FINANCIAL OFFICER

    • Officer
    121,479 2016-04-08 0

    SCHOENHARD GRANT CHIEF SCIENTIFIC OFFICER

    • Officer
    78,551 2014-07-11 0

    SABRETOOTH MASTER FUND, L.P.

    SABRETOOTH CAPITAL PARTNERS, LLC

    SABRETOOTH CAPITAL MANAGEMENT, LLC

    KALIR EREZ

    PERRY CRAIG

    • 10% Owner
    No longer subject to file 2011-10-03 0

    EASTBOURNE CAPITAL MANAGEMENT LLC/CA

    • 10% Owner
    No longer subject to file 2009-09-25 0

    BLACK BEAR OFFSHORE MASTER FUND LP

    • 10% Owner
    No longer subject to file 2009-07-01 0

    LOUCKS VERNON R JR

    • Director
    185,000 2007-09-21 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days

    COOK ROBERT CHRISTOPHER - Officer SVP & GENERAL COUNSEL

    2022-10-31 16:54:36 -0400 2022-10-28 A 100,000 $36.76 a 100,000 direct

    FRIEDMANN NADAV - Director - Officer CHIEF MEDICAL OFFICER

    2022-10-03 18:01:42 -0400 2022-10-03 M 9,376 $0.95 a 79,910 direct -1.7977 -14.5733 -3.883 1.5101 3 -20.2301 12

    FRIEDMANN NADAV - Director - Officer CHIEF MEDICAL OFFICER

    2022-10-03 18:01:42 -0400 2022-10-03 M 9,376 $0.95 d 40,624 direct

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    CASSAVA SCIENCES INC SAVA 2022-11-25 22:15:03 UTC -19.6523 23.4723 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 21:45:04 UTC -19.6523 23.4723 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 21:15:03 UTC -19.6523 23.4723 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 20:45:03 UTC -19.6041 23.4241 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 20:15:03 UTC -19.6041 23.4241 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 19:45:04 UTC -19.6041 23.4241 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 19:15:03 UTC -19.6041 23.4241 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 18:45:03 UTC -19.6038 23.4238 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 18:15:03 UTC -19.6038 23.4238 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 17:45:04 UTC -19.6038 23.4238 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 17:15:03 UTC -19.6038 23.4238 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 16:45:04 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 16:15:03 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 15:45:03 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 15:15:03 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 14:45:04 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 14:15:04 UTC -19.3846 23.2046 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 13:45:03 UTC -19.6672 23.4872 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 13:15:03 UTC -19.6672 23.4872 350000
    CASSAVA SCIENCES INC SAVA 2022-11-25 12:45:03 UTC -19.6672 23.4872 350000

    Current Active Short Positions

    Get more info on our International short position coverage here

    Holder Issuer Net Short Position Position Date Origin

    Short Position History (International Only)

    Holder Net Short Position Position Date Origin
    Squarepoint Ops LLC Cassava Sciences Inc 0.73% 2019-07-19 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 0.8% 2019-09-19 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 0.91% 2019-09-25 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 1.01% 2019-09-27 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 1.1% 2019-10-03 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 1.09% 2019-11-15 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 0.97% 2019-11-26 GERMANY
    Squarepoint Ops LLC Cassava Sciences Inc 0.88% 2019-12-06 GERMANY

    Congressional Transactions Past 6-Months

    To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***
    Congress Person Party Chamber Filing Filing Date Transaction Date Security Type Owner Transaction Amount
    Hon. Christopher L. Jacobs republican House Filing 2022-11-11 2022-10-12 P $1,001-$15,000
    representative Christopher L. Jacobs republican House Filing 2022-08-10 2022-07-18 S $1,001-$15,000
    representative Christopher L. Jacobs republican House Filing 2022-07-18 2022-06-21 P $15,001-$50,000

    Elevate your investments